MedCity News
Beam makes $120M bet that GuideTx’s tech brings gene editing beyond the liver
Base-editing biotech Beam Therapeutics engineered an all-stock buyout of Guide Therapeutics, a startup that finds, in vivo, the lipid nanoparticles that can deliver genetic medicines. Beam said GuideTx’s tech helps it address tissue types throughout the body, not just the liver.
Shares0
The next hurdles for gene-editing medicines are therapies that do their work inside the patient. But so far, biotechs have had a hard time developing such in vivo therapies that target anything other than the liver. Beam Therapeutics has acquired a startup whose technology could deliver the biotech’s genetic medicines to more tissues in the body, broadening the potential to address more diseases.
The week ahead: UK unemployment rate; HSBC, Lloyds results
cmcmarkets.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cmcmarkets.com Daily Mail and Mail on Sunday newspapers.
Andrej i Elena su svojoj deci poslednji put pokazali baku i deku kad su imali 11 godina: Primetili su mnogo sumnjivih detelja, a nakon par pitanja, VIŠE IH NISU VIDELI
zena.blic.rs - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zena.blic.rs Daily Mail and Mail on Sunday newspapers.